-
复发性口腔溃疡(recurrent oral ulcer, ROU)是常见的口腔损伤性疾病,调查[1]显示人群中10%~25%患有此病,且女性好发于男性。ROU临床表现主要有剧烈疼痛、灼热难忍等,对病人生活造成了极大的困扰。免疫功能低下的病人,一旦患有口腔溃疡,往往反复发作,病期延长[2]。ROU的发病机制错综复杂,目前临床上尚无统一定论,但有研究[3]显示,免疫因素尤其是T细胞免疫在ROU的发生中有着重要作用。还有研究[4-5]表明,在ROU发病过程中,肿瘤坏死因子-α(TNF-α)异常释放,而TNF-α具有调节免疫的功能,其异常释放可致病人发生口腔溃疡。目前临床上主要采取中医、西医加饮食调理等对症治疗的方法。近年来,有研究[6]报道,马齿苋在治疗ROU方面具有一定疗效。马齿苋为一年生肉质草本植物,我国各地均产,为药食两用植物,其营养丰富。中药马齿苋具有清热解毒、散血消肿、止血凉血、杀菌抗炎等功效。现代药理学研究[7-9]表明,马齿苋能够增强组织修复,促进溃疡愈合,此外,还可降低血糖浓度,增强抗炎、抗菌能力,提高机体免疫力等。鉴于此,本研究通过观察马齿苋提取物治疗大鼠口腔溃疡的疗效,初步探讨其对大鼠细胞免疫、炎性因子的影响,以期为临床用药提供参考。
-
各组大鼠口腔溃疡数目、持续时间差异均有统计学意义(P < 0.01),且马齿苋提取物组大鼠的口腔溃疡数目及持续时间显著低于口腔溃疡散组和模型对照组(P < 0.05~P < 0.01),口腔溃疡散组显著低于模型对照组(P < 0.01和P < 0.05)(见表 1)。
分组 n 持续时间/d 溃疡数目/个 模型对照组 8 6.3±1.6 7.9±1.9 口腔溃疡散组 8 4.7±1.3* 3.8±1.2** 马齿苋提取物组 8 3.1±0.8**# 1.6±0.6**## F — 12.56 45.35 P — <0.01 <0.01 MS组内 — 1.630 1.803 q检验:与模型对照组比较*P<0.05,**P<0.01;与口腔溃疡散组比较#P<0.05,##P<0.01 表 1 各组口腔溃疡大鼠溃疡数目、持续时间比较(x±s)
-
马齿苋提取物组小鼠治疗效果优于口腔溃疡散组与模型对照组,口腔溃疡散组小鼠临床效果优于模型对照组(P < 0.05) (见表 2)。
分组 n 痊愈 显效 无效 总有效率 Z P 模型对照组 8 0(0.0) 0(0.0) 8(100.0) 0(0.0) 口腔溃疡散组* 8 1(12.5) 4(50) 3(37.5) 5(62.5) 17.50 <0.01 马齿苋提取物组# 8 5(62.5) 2(25) 1(12.5) 7(87.5) 与模型对照组比较*P<0.05;与口腔溃疡散组比较#P<0.05 表 2 不同药物对大鼠口腔溃疡的治疗效果比较[n;百分率(%)]
-
各组大鼠炎性因子水平差异均有统计学意义(P < 0.01),且血清IFN-γ水平,模型对照组水平显著低于空白对照组,口腔溃疡散组与马齿苋提取物组明显高于模型对照组,马齿苋提取物组高于口腔溃疡散组(P < 0.05~P < 0.01)。血清TNF-α和IL-2水平,模型对照组较空白对照组明显升高,口腔溃疡散组、马齿苋提取物组低于模型对照组(P < 0.01),马齿苋提取物组与口腔溃疡散组间差异无统计学意义(P>0.05)(见表 3)
分组 n IFN-γ TNF-α IL-2 正常对照组 8 162.7±23.5 138.7±22.3 38.6±4.6 模型对照组 8 94.6±21.2** 219.6±21.4** 61.3±3.7** 口腔溃疡散组 8 124.1±16.3*## 152.5±13.8## 49.6±3.9** 马齿苋提取物组 8 149.4±15.7##▲ 146.3±12.4## 47.4±2.8**## F — 19.06 34.28 48.30 P — <0.01 <0.01 <0.01 MS组内 — 378.468 324.863 14.475 q检验:与正常对照组比较*P<0.05,**P<0.01;与模型对照组比较##P<0.01;与口腔溃疡散组比较▲P < 0.05 表 3 不同药物治疗后大鼠炎性因子水平比较(x±s;ng/L)
-
各组大鼠T淋巴细胞亚群水平差异均有统计学意义(P < 0.01),且模型对照组CD3+、CD4+和CD4+/CD8+水平显著低于空白对照组,CD8+水平显著高于空白对照组(P < 0.01);口腔溃疡散组与马齿苋提取液组CD3+、CD4+和CD4+/CD8+水平均高于模型组,而CD8+均低于模型对照组(P < 0.05~P < 0.01),马齿苋提取液组CD3+、CD4+和CD4+/CD8+水平均明显高于口腔溃疡散组(P < 0.05~P < 0.01) (见表 4)。
分组 n CD3+ CD4+ CD4+/CD8+ CD8+ 正常对照组 8 39.4±3.1 28.3±2.9 2.3±0.4 12.3±2.4 模型对照组 8 24.3±3.5** 19.6±4.4** 1.1±0.2** 18.7±3.5** 口腔溃疡散组 8 29.1±6.2** 23.5±3.8*# 1.5±0.3**# 15.5±2.3# 马齿苋提取物组 8 36.4±5.7##▲▲ 27.3±2.1##▲ 2.2±0.4##▲▲ 13.1±1.4## F — 16.26 10.79 23.41 10.47 P — <0.01 <0.01 <0.01 <0.01 MS组内 — 23.198 11.655 0.113 6.315 q检验:与正常对照组比较*P<0.05,**P<0.01;与模型对照组比较#P<0.05,##P<0.01;与口腔溃疡散组比较▲P < 0.05,▲▲P < 0.01 表 4 不同药物治疗后大鼠T淋巴细胞亚群水平比较(x±s;%)
马齿苋提取物治疗大鼠口腔溃疡的疗效及其对细胞免疫、炎性因子的影响
Efficacy of purslane extract in the treatment of oral ulcer, and its effects on cellular immunity and inflammatory factors in rats
-
摘要:
目的观察马齿苋提取物治疗大鼠口腔溃疡的疗效,初步探讨其对大鼠细胞免疫、炎性因子的影响,以期为临床用药提供参考。 方法采用抗原乳化液方法建立大鼠口腔溃疡模型,实验设有空白对照组、模型对照组(不给予药物处理)、口腔溃疡散组(6%口腔溃疡散混悬液涂抹)以及马齿苋提取物组(0.24 g/mL马齿苋水溶液灌胃),每组8只大鼠。观察各组大鼠口腔溃疡数目、持续时间以及治疗效果。比较各组大鼠的血清干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)水平以及T细胞亚群水平变化情况。 结果各组大鼠口腔溃疡数目、持续时间差异均有统计学意义(P < 0.01),且马齿苋提取物组显著低于口腔溃疡散组和模型对照组(P < 0.05~P < 0.01),口腔溃疡散组显著低于模型对照组(P < 0.01和P < 0.05)。口腔溃疡散组小鼠治疗效果优于模型对照组,马齿苋提取物组小鼠治疗效果优于口腔溃疡散组与模型对照组(P < 0.05)。各组大鼠炎性因子水平差异均有统计学意义(P < 0.01),且血清IFN-γ水平,模型对照组显著低于空白对照组,口腔溃疡散组与马齿苋提取物组明显高于模型对照组,马齿苋提取物组高于口腔溃疡散组(P < 0.05~P < 0.01);血清TNF-α和IL-2水平,模型对照组较空白对照组明显升高,口腔溃疡散组、马齿苋提取物组低于模型对照组(P < 0.01),马齿苋提取物组与口腔溃疡散组间差异无统计学意义(P>0.05)。各组大鼠T淋巴细胞亚群水平差异均有统计学意义(P < 0.01),且模型对照组CD3+、CD4+和CD4+/CD8+水平显著低于空白对照组,CD8+水平显著高于空白对照组(P < 0.01);口腔溃疡散组与马齿苋提取液组CD3+、CD4+和CD4+/CD8+水平均高于模型组,而CD8+均低于模型对照组(P < 0.05~P < 0.01),马齿苋提取液组CD3+、CD4+和CD4+/CD8+水平均明显高于口腔溃疡散组(P < 0.05~P < 0.01)。 结论马齿苋提取物可有效缩短大鼠溃疡持续时间,减少溃疡数目,提高溃疡治疗效率。其机制可能是通过增强机体免疫功能以治疗复合性口腔溃疡。 Abstract:ObjectiveTo observe the therapeutic effects of purslane extract on oral ulcer, and explore its effects on cellular immunity and inflammatory factors in rats, to provide reference for clinical drug use. MethodsThe rat oral ulcer model was established by antigen emulsion method.The rats were divided into the blank control group, model control group (no medication), oral ulcer powder group (treatment with oral ulcer powder suspension painting) and purslane extract group (treatment with purslane solution gavage) (8 rats each group).The number, duration and therapeutic effect of oral ulcer in all groups were observed.The levels of serum interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and T cell subsets were compared among all groups. ResultsThe differences of the number and duration of oral ulcer among all groups were statistically significant (P < 0.01), which in purslane extract group were significantly lower than those in oral ulcer powder group and model control group (P < 0.05 to P < 0.01), and which in oral ulcer powder group was significantly lower than that in model control group (P < 0.01 and P < 0.05).The therapeutic effect in oral ulcer powder group was better than that in model control group, and which in purslane extract group was better than that in oral ulcer powder group and model control group (P < 0.05).The differences of the serum levels of inflammatory factors among all groups were statistically significant (P < 0.01), the serum level of IFN-γ in model control group was significantly lower than that in blank control group, the serum levels of IFN-γ in oral ulcer powder group and purslane extract group were significantly higher than that in model control group, and the serum level of IFN-γ in purslane extract group was higher than that in oral ulcer powder group (P < 0.05 to P < 0.01).The serum levels of TNF-α and IL-2 in model control group significantly increased compared with the blank control group, which in oral ulcer powder group and purslane extract group were lower than those in model control group (P < 0.01), and the differences of the serum levels of TNF-α and IL-2 between oral ulcer powder group and purslane extract group were not statistically significant (P>0.05).The differences of the T lymphocyte subsets levels among all groups were statistically significant (P < 0.01), the levels of CD3+、CD4+ and CD4+/CD8+ in model control group were significantly lower than those in blank control group, and the serum level of CD8+ in model control group was significantly higher than that in blank control group (P < 0.01).The serum levels of CD3+, CD4+ and CD4+/CD8+ in oral ulcer powder group and purslane extract group were higher than those in model control group (P < 0.01), the serum levels of CD8+ in oral ulcer powder group and purslane extract group were lower than that in model control group (P < 0.01), and the serum levels of CD3+, CD4+ and CD4+/CD8+ in purslane extract group were significantly higher than those in oral ulcer powder group (P < 0.05 to P < 0.01). ConclusionsThe purslane extract can effectively shorten the duration of ulcer, reduce the number of ulcers, and improve the efficiency of ulcer treatment.Its mechanism may be retated to enhance the immune function of body. -
Key words:
- oral ulcer /
- purslane extract /
- oral ulcer powder /
- inflammatory factor /
- T lymphocyte
-
表 1 各组口腔溃疡大鼠溃疡数目、持续时间比较(x±s)
分组 n 持续时间/d 溃疡数目/个 模型对照组 8 6.3±1.6 7.9±1.9 口腔溃疡散组 8 4.7±1.3* 3.8±1.2** 马齿苋提取物组 8 3.1±0.8**# 1.6±0.6**## F — 12.56 45.35 P — <0.01 <0.01 MS组内 — 1.630 1.803 q检验:与模型对照组比较*P<0.05,**P<0.01;与口腔溃疡散组比较#P<0.05,##P<0.01 表 2 不同药物对大鼠口腔溃疡的治疗效果比较[n;百分率(%)]
分组 n 痊愈 显效 无效 总有效率 Z P 模型对照组 8 0(0.0) 0(0.0) 8(100.0) 0(0.0) 口腔溃疡散组* 8 1(12.5) 4(50) 3(37.5) 5(62.5) 17.50 <0.01 马齿苋提取物组# 8 5(62.5) 2(25) 1(12.5) 7(87.5) 与模型对照组比较*P<0.05;与口腔溃疡散组比较#P<0.05 表 3 不同药物治疗后大鼠炎性因子水平比较(x±s;ng/L)
分组 n IFN-γ TNF-α IL-2 正常对照组 8 162.7±23.5 138.7±22.3 38.6±4.6 模型对照组 8 94.6±21.2** 219.6±21.4** 61.3±3.7** 口腔溃疡散组 8 124.1±16.3*## 152.5±13.8## 49.6±3.9** 马齿苋提取物组 8 149.4±15.7##▲ 146.3±12.4## 47.4±2.8**## F — 19.06 34.28 48.30 P — <0.01 <0.01 <0.01 MS组内 — 378.468 324.863 14.475 q检验:与正常对照组比较*P<0.05,**P<0.01;与模型对照组比较##P<0.01;与口腔溃疡散组比较▲P < 0.05 表 4 不同药物治疗后大鼠T淋巴细胞亚群水平比较(x±s;%)
分组 n CD3+ CD4+ CD4+/CD8+ CD8+ 正常对照组 8 39.4±3.1 28.3±2.9 2.3±0.4 12.3±2.4 模型对照组 8 24.3±3.5** 19.6±4.4** 1.1±0.2** 18.7±3.5** 口腔溃疡散组 8 29.1±6.2** 23.5±3.8*# 1.5±0.3**# 15.5±2.3# 马齿苋提取物组 8 36.4±5.7##▲▲ 27.3±2.1##▲ 2.2±0.4##▲▲ 13.1±1.4## F — 16.26 10.79 23.41 10.47 P — <0.01 <0.01 <0.01 <0.01 MS组内 — 23.198 11.655 0.113 6.315 q检验:与正常对照组比较*P<0.05,**P<0.01;与模型对照组比较#P<0.05,##P<0.01;与口腔溃疡散组比较▲P < 0.05,▲▲P < 0.01 -
[1] 刘好好, 许子悦, 谢春雨, 等.复发性口腔溃疡与T细胞免疫研究进展[J].现代免疫学, 2016, 36(1):72. [2] 王斌, 陈丽君, 赵玺, 等.雷尼替丁治疗老年复发性口腔溃疡的疗效及对细胞免疫、炎性因子的影响[J].疑难病杂志, 2018, 17(1):59. [3] 管翠强, 郭洪波, 武云霞, 等.复发性口腔溃疡患者的氧化应激与细胞免疫状态研究[J].中国药物与临床, 2018, 18(6):884. [4] 邹玉红, 杨静, 陈春华.复发性口腔溃疡患者血清中TNF-α、IL-2, 6与免疫功能的相关性[J].海南医学院学报, 2015, 21(9):1299. [5] 陈远东, 杨海, 邱海山, 等.复发性口腔溃疡患者血清中TNF-α、IL-2及T淋巴细胞亚群的变化[J].海南医学, 2017, 28(1):94. doi: 10.3969/j.issn.1003-6350.2017.01.029 [6] 郑丽明, 欧江勇, 黄秀云.马齿苋治疗复发性口腔溃疡的疗效及其对血清中IL-8、TNF-α的影响[J].中国医药科学, 2017, 7(8):25. doi: 10.3969/j.issn.2095-0616.2017.08.007 [7] JIN TY, SHEN T, ZHOU MX, et al.Chemincal constituents from Portulaca oleracea and their bioactivities[J].J Chin Pharm Sci, 2016, 25(12):898. [8] 施文彩, 薛凡, 李菊红, 等.马齿苋的药理活性研究进展[J].药学服务与研究, 2016, 16(4):291. [9] 克里斯, 郭建状, 杨景云, 等.马齿苋多糖对衰老小鼠免疫调节作用的研究[J].黑龙江医药科学, 2012, 35(2):27. doi: 10.3969/j.issn.1008-0104.2012.02.015 [10] 杨志诚, 吴丽芳, 郭其, 等.复方黄连消疮灵治疗复发性口腔溃疡的免疫学机制研究[J].中医药信息, 2018, 35(2):50. [11] 李向荣, 刘晓丽.大剂量维生素C治疗化疗所致口腔溃疡的临床疗效观察[J].医学综述, 2015, 21(8):1499. doi: 10.3969/j.issn.1006-2084.2015.08.059 [12] 刘祖祥, 朱双雪, 王劲, 等.生地黄芩麦冬方联合复方口腔溃疡膜剂治疗复发性口腔溃疡的临床效果研究[J].中药药理与临床, 2015, 31(1):250. [13] 卢敏, 胡艺平, 吴珠燕, 等.复发性口腔溃疡患者血浆炎症因子的变化及干扰素α-2b的干预作用[J].海峡药学, 2012, 24(5):89. doi: 10.3969/j.issn.1006-3765.2012.05.043 [14] SHARDA N, SHASHIKANTH MC, KANT P, et al.Levamisole and low-dose prednisolone in the treatment of reccurent aphthous stomatitis[J].J Oral Pathol Med, 2014, 43(4):309. doi: 10.1111/jop.12126 [15] 王明海, 焦学高, 钟正华, 等.复发性口腔溃疡患者血清肿瘤坏死因子α变化及组织病理学改变[J].吉林医学, 2014, 35(36):8075. doi: 10.3969/j.issn.1004-0412.2014.36.051 [16] ZIAUDEEN S, RAVINDRAN R.Assessment of oxidant-antioxidant status and stress factor in recurrent aphthous stomatitis patients:case control study[J].J Clin Diagn Res, 2017, 11(3):C1. [17] YOON BN, KIM SJ, LIM MJ, et al.Neuro-Behcet's disease presenting as hypertrophic pachymeningitis[J].Exp Neurobiol, 2015, 24(3):252. doi: 10.5607/en.2015.24.3.252 [18] 马晓喆, 李言君, 付爱丽, 等.IFN-γR和sIL-2R在复发性口腔溃疡患者血浆中的表达及意义[J].实用口腔医学杂志, 2015, 31(5):656. doi: 10.3969/j.issn.1001-3733.2015.05.013 [19] 周玉龙, 林华清.口腔溃疡含片和口腔溃疡散治疗复发性阿弗他溃疡的效果比较[J].泰山医学院学报, 2014, 35(5):389. doi: 10.3969/j.issn.1004-7115.2014.05.018 [20] 曹凤.中药内外合治复发性阿弗他溃疡64例[J].中国中医药科技, 2018, 25(2):279. [21] 施文彩, 薛凡, 李菊红, 等.马齿苋的药理活性研究进展[J].药学服务与研究, 2016, 16(4):291.